Please use this identifier to cite or link to this item:
Title: Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).
Austin Authors: Ellis, Kathryn A;Szoeke, Cassandra;Bush, Ashley I;Darby, David G;Graham, Petra L;Lautenschlager, Nicola T;Macaulay, S Lance;Martins, Ralph N;Maruff, Paul;Masters, Colin L ;McBride, Simon J;Pike, Kerryn E;Rainey-Smith, Stephanie R;Rembach, Alan;Robertson, Joanne;Rowe, Christopher C ;Savage, Greg;Villemagne, Victor L ;Woodward, Michael M ;Wilson, William;Zhang, Ping;Ames, David
Institutional Author: AIBL Research Group
Affiliation: Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia
CogState Limited, Melbourne, Victoria, Australia
Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne; St. Vincent's Aged Psychiatry Service, St George's Hospital, Kew, Victoria, Australia
Commonwealth Scientific and Industrial Research Organisation, Preventative Health Flagship, CMSE CMIS (CSIRO), Parkville, Victoria, Australia
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Latrobe University, Melbourne, Victoria, Australia
Austin Health, Aged Care, Heidelberg, Victoria, Australia
Macquarie University, Sydney, NSW, Australia
National Ageing Research Institute (NARI), Parkville, Victoria, Australia
Florey Institute of Neuroscience and Mental Health (MHRI), Parkville, Victoria, Australia
Issue Date: 20-Nov-2013
Publication information: International Psychogeriatrics / Ipa 2013; 26(4): 543-54
Abstract: The Australian Imaging, Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing is a prospective study of 1,112 individuals (211 with Alzheimer's disease (AD), 133 with mild cognitive impairment (MCI), and 768 healthy controls (HCs)). Here we report diagnostic and cognitive findings at the first (18-month) follow-up of the cohort. The first aim was to compute rates of transition from HC to MCI, and MCI to AD. The second aim was to characterize the cognitive profiles of individuals who transitioned to a more severe disease stage compared with those who did not.Eighteen months after baseline, participants underwent comprehensive cognitive testing and diagnostic review, provided an 80 ml blood sample, and completed health and lifestyle questionnaires. A subgroup also underwent amyloid PET and MRI neuroimaging.The diagnostic status of 89.9% of the cohorts was determined (972 were reassessed, 28 had died, and 112 did not return for reassessment). The 18-month cohort comprised 692 HCs, 82 MCI cases, 197 AD patients, and one Parkinson's disease dementia case. The transition rate from HC to MCI was 2.5%, and cognitive decline in HCs who transitioned to MCI was greatest in memory and naming domains compared to HCs who remained stable. The transition rate from MCI to AD was 30.5%.There was a high retention rate after 18 months. Rates of transition from healthy aging to MCI, and MCI to AD, were consistent with established estimates. Follow-up of this cohort over longer periods will elucidate robust predictors of future cognitive decline.
DOI: 10.1017/S1041610213001956
Journal: International psychogeriatrics / IPA
Type: Journal Article
Subjects: Aged
Aged, 80 and over
Alzheimer Disease.blood.diagnosis
Biological Markers.blood
Case-Control Studies
Disease Progression
Follow-Up Studies
Life Style
Magnetic Resonance Imaging
Middle Aged
Mild Cognitive Impairment.blood.diagnosis
Neuropsychological Tests.statistics & numerical data
Positron-Emission Tomography
Prospective Studies
Socioeconomic Factors
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Feb 27, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.